Johanna Hilli

Summary

Affiliation: University of Turku
Country: Finland

Publications

  1. ncbi Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population
    Johanna Hilli
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Itainen Pitkakatu 4B, 3rd Floor, FIN 20520 Turku, Finland
    Fundam Clin Pharmacol 21:379-86. 2007
  2. doi The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism
    Johanna Hilli
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Itainen Pitkakatu 4B, 3rd Floor, FIN 20520 Turku, Finland
    J Clin Pharmacol 48:986-94. 2008
  3. doi MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs
    Johanna Hilli
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland
    Eur Neuropsychopharmacol 19:363-70. 2009
  4. doi Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram
    Johanna Hilli
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland
    Prog Neuropsychopharmacol Biol Psychiatry 33:1526-32. 2009
  5. doi NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer
    Johanna Hilli
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Itainen Pitkakatu 4B, 3rd Floor, 20520 Turku, Finland
    Cancer Chemother Pharmacol 67:1353-62. 2011

Detail Information

Publications5

  1. ncbi Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population
    Johanna Hilli
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Itainen Pitkakatu 4B, 3rd Floor, FIN 20520 Turku, Finland
    Fundam Clin Pharmacol 21:379-86. 2007
    ..The higher than expected frequency of the CYP3A5*1*1 genotype and the CYP2C8*3*3/CYP2C9*2*2 haplotype may influence the response to treatment with drugs metabolized by these enzymes...
  2. doi The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism
    Johanna Hilli
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Itainen Pitkakatu 4B, 3rd Floor, FIN 20520 Turku, Finland
    J Clin Pharmacol 48:986-94. 2008
    ..In conclusion, a significant inhibitory effect of OCs on the CYP1A2-catalyzed melatonin metabolism was seen; thereby, OC use can alter CYP1A2-phenotyping results...
  3. doi MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs
    Johanna Hilli
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland
    Eur Neuropsychopharmacol 19:363-70. 2009
    ..The COMT 1947G>A polymorphism may affect the occurrence of respiratory distress symptoms in infants with prenatal SSRI-exposure via a mechanism involving prolactin...
  4. doi Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram
    Johanna Hilli
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland
    Prog Neuropsychopharmacol Biol Psychiatry 33:1526-32. 2009
    ..To evaluate the potential of pharmacodynamic and pharmacokinetic interactions of a concomitantly administered monoamine oxidase (MAO) type B inhibitor rasagiline and a selective serotonin reuptake inhibitor (SSRI) escitalopram...
  5. doi NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer
    Johanna Hilli
    Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Itainen Pitkakatu 4B, 3rd Floor, 20520 Turku, Finland
    Cancer Chemother Pharmacol 67:1353-62. 2011
    ..To study the CYP3A activity before and after docetaxel administration. Furthermore, it was investigated whether peroral midazolam could predict docetaxel exposure and adverse events...